- New data from the British health authority Public Health England (PHE) has shown that
the AstraZeneca COVID-19 vaccine offers high levels of protection against the Delta
(formerly Indian)
variant
.
This was announced by AstraZeneca. Real-world data from PHE, published as prepress, showed that
2 doses of the vaccine were 92% effective
against hospitalization due to the Delta variant and showed no deaths among vaccinated. The vaccine also showed a high level of efficacy against the Alpha (formerly English) variant with an 86% reduction in hospitalizations and no deaths reported.
The data, the company says, suggests that the vaccine's efficacy against milder, albeit significant, symptomatic disease was lower. The efficacy of the AstraZeneca vaccine against symptomatic disease was 74% against the Alpha variant and 64% against the Delta variant. The increased efficacy against severe illness and hospitalization, AztraZeneca also notes, "is supported by recent data showing a strong T-cell response to the COVID-19 AstraZeneca vaccine, which should be correlated with high and long-lasting protection." The analysis included 14,019 cases of the Delta variant - 166 of which were hospitalized - between April 12 and June 4, looking at emergency hospital admissions in England. This real-world test against the Delta variant,AstraZeneca points out, "it is based on limited follow-up after the second dose, which could affect the estimate of efficacy." Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, said, "This real-world evidence shows that the AstraZeneca COVID-19 vaccine provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid The data shows that the vaccine will continue to have a significant impact worldwide, as it continues to account for the vast majority of supplies to India and the COVAX initiative. "Executive Vice President BioPharmaceuticals R&D said, “This real-world evidence shows that the AstraZeneca COVID-19 vaccine provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission. data shows that the vaccine will continue to have a significant impact worldwide, as it continues to account for the vast majority of supplies to India and the COVAX initiative. "Executive Vice President BioPharmaceuticals R&D said, “This real-world evidence shows that the AstraZeneca COVID-19 vaccine provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission. data shows that the vaccine will continue to have a significant impact worldwide, as it continues to account for the vast majority of supplies to India and the COVAX initiative. "The data show that the vaccine will continue to have a significant impact around the world as it continues to account for the vast majority of supplies to India and the COVAX initiative. "The data show that the vaccine will continue to have a significant impact around the world as it continues to account for the vast majority of supplies to India and the COVAX initiative. "
